A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma

This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG, Amgen (Neupogen)

Final Accrual

20

Trial Chairperson

Dr Peter O’Brien, Calvary Mater Newcastle, NSW

Clinical Trial Registration

Related Post

21 October, 2026

Jess’s deeply personal reason for joining TROG’s Km’s for Cancer Research challenge

LATEST NEWS: 21 October 2026 For Jess Synge, taking

14 October, 2026

New FET-PET imaging approach helps target radiotherapy for glioblastoma, FIG trial – TROG 18.06 finds

LATEST NEWS: 14 October 2026 Adding a FET-PET brain